Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Mar 31, 2026

Karman Holdings (KRMN): Strong Backlog and Leadership Drive +53% Revenue Growth Outlook

Key Takeaways

  • Karman Holdings' $1 billion+ backlog supports raised FY2026 revenue guidance of $715-730 million, signaling robust demand in hypersonics, missile defense, and space.
  • New CEO Jon Rambeau, a defense veteran, positions the company for accelerated growth through production ramps and strategic acquisitions.
  • Analyst consensus leans "Moderate Buy" with an average price target of $117.10, implying significant upside amid rising U.S. defense budgets.
  • Industry tailwinds from multi-year procurement contracts and space economy expansion bolster medium-term positioning.
  • Macro sensitivities include sustained defense spending increases and geopolitical tensions driving missile/UAS demand.
  • Key risks involve execution on capacity expansions, margin pressure from investments, and potential budget delays.

Strategic Positioning and Competitive Outlook

In my view, Karman Holdings Inc. (KRMN) really stands out in the aerospace and defense sector with its focus on mission-critical subsystems, including payload protection and deployment systems, aerodynamic interstage systems, and propulsion systems. The company serves high-growth markets like hypersonics, strategic missile defense, tactical missiles, and space launch, benefiting from proprietary engineering and manufacturing capabilities that enable rapid development for prime contractors.

With facilities across the U.S., Karman is scaling production through recent investments exceeding $15 million, complemented by $5 million in Defense Production Act (DPA) funding for solid rocket motor nozzles. Acquisitions like Seemann Composites expand into maritime defense, diversifying revenue while maintaining high EBITDA margins. From what I see, this positions Karman favorably against peers, leveraging a $1 billion+ backlog for multi-year visibility in a sector poised for structural growth driven by U.S. Department of Defense priorities. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Major Catalysts Ahead

Karman's trajectory hinges on several near-term drivers. Q1 FY2026 earnings, estimated around May 2026, will provide updates on backlog conversion and guidance progress, with consensus expecting $150 million in revenue and $0.11 EPS. The new Utah facility, set for Q4 2026 readiness, will quadruple UAS launcher and SRM nozzle capacity, aligning with Pentagon munitions priorities.

A $151 billion ceiling Missile Defense Agency SHIELD contract offers long-term opportunity in layered defense systems. Recent credit facility expansion to $150 million supports M&A (mergers and acquisitions) and capex. Analyst actions remain positive: Citi raised its target to $127, Needham initiated Buy at $125, with consensus at $117.10 from 11 firms (Moderate Buy). Upward revisions reflect optimism on 53% revenue growth, though one Sell notes free cash flow risks. One thing that stands out is how these developments align with broader defense priorities.

Industry and Macroeconomic Forces

The aerospace and defense industry faces tailwinds from escalating geopolitical risks, prompting U.S. defense budget hikes—missile procurement and RDT&E (research, development, test, and evaluation) funding up 73% to $63 billion in FY26. Karman's exposure to hypersonics, UAS (unmanned aircraft systems), and space aligns with multi-year contracts stabilizing demand.

Interest rates impact capex but lower rates could ease funding for primes. Inflation affects supply chains, yet DPA funding mitigates costs. Expanding space economy and naval programs via acquisitions enhance resilience. Risks include budget sequestration or shifts in policy priorities. This is important because sustained defense spending remains a key macro sensitivity I'm watching closely.

Discovering Trends with Tickeron’s AI Tools

As part of my research process, I rely on Tickeron’s Trend Prediction Engine, an AI-powered forecasting tool that helps identify whether a stock like KRMN, an ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It analyzes vast datasets to spot developing trends, evaluate possible breakouts or reversals, and deliver predictions across thousands of tradable instruments. Features include searchable prediction categories by timeframe and confidence level, historical performance context for patterns, and customizable alerts for real-time notifications on shifts. I find it particularly useful for both novice and experienced users, empowering informed decision-making amid market volatility. If you're looking to enhance your trading strategy, exploring the Trend Prediction Engine has been a valuable addition to my toolkit.

2026 Outlook and Long-Term Themes to Watch

For 2026, Karman guides $715-730 million revenue (53% growth) and $207-218 million adjusted EBITDA, backed by a $1 billion backlog surpassing $801 million at FY2025 end. Consensus aligns closely at $726 million revenue and $0.66 EPS, with 27% revenue growth into 2027. Key themes include margin expansion to 42%+ via scale, Utah facility ramp, and maritime entry post-Seemann acquisition.

Longer-term, watch U.S. defense supercycle, space commercialization, and tech transitions like AI-enabled manufacturing. Competitive threats from larger primes loom, but niche expertise sustains moats. Capital allocation prioritizes capacity and bolt-ons; regulatory tailwinds from munitions focus persist. Analyst expectations of 53% EPS growth underscore sentiment, though execution risks remain. I think these factors make for a compelling medium-term story.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: KRMN

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for KRMN turns negative, indicating new downward trend

KRMN saw its Momentum Indicator move below the 0 level on September 28, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator turned negative. In 20 of the 24 cases, the stock moved further down in the following days. The odds of a decline are at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for KRMN crossed bearishly below the 50-day moving average on August 31, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 2 of 3 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for KRMN entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KRMN's RSI Oscillator exited the oversold zone, 7 of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for KRMN just turned positive on September 24, 2026. Looking at past instances where KRMN's MACD turned positive, the stock continued to rise in 9 of 13 cases over the following month. The odds of a continued upward trend are 69%.

Following a +7.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRMN advanced for three days, in 97 of 105 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.604) is normal, around the industry mean (6.305). P/E Ratio (124.741) is within average values for comparable stocks, (58.116). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (8.299) is also within normal values, averaging (18.330).

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. KRMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 38.94B. The market cap for tickers in the group ranges from 4.49 to 1.92T. SPCX holds the highest valuation in this group at 1.92T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -3%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -12%. ELMT experienced the highest price growth at 13%, while KITT experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 26%. For the same stocks of the Industry, the average monthly volume growth was 47% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 70
Price Growth Rating: 62
SMR Rating: 77
Profit Risk Rating: 76
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
KRMN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry AerospaceDefense

Industry
N/A
Address
5351 Argosy Avenue
Phone
+1 714 898-9951
Employees
1400
Web
https://www.karman-sd.com
Interact to see
Advertisement
I've been following Planet Labs PBC (PL) closely, and one aspect that stands out is its operation of the world's largest constellation of earth-imaging satellites. This setup delivers daily global coverage, giving it a clear edge in geospatial intelligence. The "one-to-many" model allows for scalable economics, setting it apart from legacy providers that depend on exclusive image sales. The platform combines satellite data with AI-driven analytics, targeting sectors such as agriculture, defense, forestry, and insurance.
United Therapeutics Corporation focuses on biotechnology innovations for chronic and life-threatening conditions, particularly in pulmonary diseases. The company's portfolio centers on treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), featuring products like Tyvaso (treprostinil inhalation solution), Orenitram (oral treprostinil), Remodulin, and Adcirca.
I've been following Rocket Pharmaceuticals (RCKT) closely as a late-stage biotech focused on gene therapies for rare pediatric diseases, using both lentiviral vector (LVV) and adeno-associated virus (AAV) platforms. What stands out to me is the company's strategic shift toward AAV-based cardiovascular programs—Danon disease, PKP2-ACM, and BAG3-DCM—which target areas with significant unmet needs and larger markets compared to traditional hematology indications. The recent FDA approval of KRESLADI marks Rocket's entry into commercialization, giving the team valuable launch experience and confirming the strength of its manufacturing setup.
I've been keeping an eye on KDK, and it's clear the company is well-positioned in the autonomous vehicle space, with a focus on AI-powered solutions for long-haul trucking, industrial applications, and defense. Founded in 2018 and based in Mountain View, California, Kodiak AI develops the Kodiak Driver—a modular, vehicle-agnostic virtual driver that integrates advanced AI software with hardware to enable driverless operations. This platform tackles key challenges like U.S. truck driver shortages and safety concerns, where human error accounts for over 85% of crashes.
SE stock declined -21% over the past 30 days, primarily triggered by a Q4 2025 earnings EPS miss despite revenue beat, leading to a sharp 16% single-day drop. Over the past quarter, the stock fell -37%, reflecting sustained pressure from analyst price target cuts and concerns over rising growth investments.
As I review the cybersecurity space, PANW stands out with its commanding position, holding a 28.4% share in network security as of 2024. This leadership stems from its evolution from point solutions to a unified platform that includes Strata for network security, Prisma for cloud and SASE, and Cortex for AI-powered security operations. The platformization strategy is key here—it encourages customers to consolidate their fragmented tools, which reduces complexity and costs while driving NGS ARR growth. In Q2 FY2026, NGS ARR rose 33% year-over-year to $6.3 billion.
TaskUs, Inc. (TASK) stands out as a leading provider of outsourced digital services and next-generation customer experience solutions. The company focuses on digital customer experience (Digital CX), trust and safety (monitoring user-generated content for compliance), and artificial intelligence (AI) services such as data labeling and annotation for machine learning models. From its headquarters in New Braunfels, Texas, TaskUs serves high-growth sectors like social media, e-commerce, gaming, streaming, food delivery, ride-sharing, technology, financial services, and healthcare.
WVE stock plunged approximately -52% over the past 30 days, driven primarily by disappointing high-dose data from the Phase 1 INLIGHT trial of obesity candidate WVE-007 on March 26, which erased prior gains from positive initial results. Over the past quarter, shares declined around -61%, reflecting high volatility in biotech sentiment amid clinical trial outcomes and broader sector pressures on clinical-stage firms
KOD stock surged +39% over the past 30 days, driven primarily by positive Phase 3 GLOW2 trial results for Zenkuda in diabetic retinopathy. Over the past quarter, shares gained +36%, reflecting anticipation of clinical catalysts and a successful $184 million capital raise.
Lam Research Corporation stands out as a leading supplier of semiconductor processing equipment essential for fabricating integrated circuits. The company designs, manufactures, markets, refurbishes, and services tools for deposition, etch, and clean processes, serving major chipmakers across the United States, China, Korea, Taiwan, Japan, and Europe. At its core, Lam's business revolves around innovative systems like ALTUS for film deposition and SABRE for electrochemical deposition, which are vital for advanced nodes in AI, memory, and logic chips.
Roblox Corporation (RBLX) runs a platform where millions of users create and dive into immersive 3D experiences. The business centers on a virtual economy: users buy Robux for in-game items, and creators cash out through the developer exchange (DevEx) program. In the online gaming space, Roblox stands out as a metaverse pioneer, going up against the likes of Epic Games' Fortnite and newer AI-driven platforms. The fundamentals reflect impressive user growth—daily active users (DAUs) reached 144 million in Q4 2025, a 69% jump year-over-year—but ongoing net losses underscore the heavy spending on infrastructure, AI, and safety. From what I see, this tension between growth and profitability has fueled much of the recent volatility in RBLX shares, as investors weigh strong engagement against shrinking margins.
Megan Holdings Limited (MGN) is a Malaysia-based company focused on the development, construction, maintenance, and upgrade of aquaculture and agriculture farms, along with related services. At its core, the business provides end-to-end solutions for shrimp farms, from design and building hatcheries to ongoing maintenance. It operates mainly in Sabah, Malaysia, across segments like aquaculture/agriculture, industrial solutions such as smart technologies, and investments in marketable securities.
Megan Holdings Limited (MGN), based in Kuala Lumpur and founded in 2020, focuses on developing, constructing, maintaining, and upgrading aquaculture and agriculture farms in Malaysia. The company operates in three segments—aquaculture and agriculture, industrial solutions like supplying smart technologies and machinery rentals, and investments in marketable securities—carving out a niche in engineering and construction within the Industrials sector. Its subsidiary status under Star Sprite Limited adds a layer of operational stability.
Pony AI Inc. (PONY) stands out as a leading player in autonomous mobility, dedicated to bringing self-driving technology to commercial use. Founded in 2016 and based in Guangzhou, China, the company operates across China, the U.S., and other international markets, offering robotaxi services, robotruck logistics, and licensing for intelligent driving solutions. Its business model leans heavily on asset-light partnerships with original equipment manufacturers (OEMs), transportation network companies (TNCs), and logistics platforms.
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney and metabolic diseases. In my view, the company's core strength lies in its proprietary Maze Compass platform, which uses human genetics and variant functionalization to identify and advance therapies targeting genetically defined patient populations.
In my view, JPM stands out as the largest U.S. bank by assets and market capitalization, commanding leading market shares across key segments. It holds approximately 11.1% of U.S. retail deposits, 23.6% of credit card sales volume, 8.4% of global investment banking fees, 11.8% of markets revenue, and 10% of treasury services revenue. This diversified "universal banking model" spans consumer and community banking, commercial and investment banking, and asset and wealth management, generating resilient revenue streams.
In recent sessions, WMT has held steady around $124, pulling back from February highs near $134. From what I see, this resilience stands out as the stock has outperformed broader indices year-to-date, thanks to its defensive role in groceries and essentials. Shoppers are leaning toward value options, and consistent volumes show ongoing institutional support. The premium valuation reflects confidence in Walmart's omnichannel progress and market share gains. Even with macro headwinds, I view WMT as a portfolio staple during uncertain times.
I've been following ANTX, a biopharmaceutical company based in Menlo Park, California, that develops novel small molecule therapeutics from its proprietary boron chemistry platform. The focus is on underserved areas like infectious diseases, with the lead candidate epetraborole advancing in Phase 3 trials for non-tuberculous mycobacterial (NTM) lung disease and acute melioidosis. The pipeline also includes AN2-502998 for chronic Chagas disease in preclinical stages, along with programs in oncology.
Tilly's, Inc. (TLYS) operates as a specialty retailer specializing in casual apparel, footwear, accessories, and hardgoods aimed at young men, women, boys, and girls. The company focuses on branded fashion inspired by action sports, surf, and skate culture, offering products like tops, bottoms, swimwear, backpacks, hats, and sunglasses from well-known brands such as Vans and Hurley. With approximately 223 stores in malls and lifestyle centers, complemented by e-commerce through www.tillys.com, Tilly's effectively combines physical and digital sales channels.
NKE shares are tumbling approximately 11% in premarket trading on April 1, 2026, sliding to near nine-year lows after the previous close of $52.82. The primary catalyst is Nike's weak Q4 fiscal 2026 guidance: management projected a 2%–4% revenue decline, sharply missing analyst expectations of approximately 1.9% growth.